In addition, Rotkrua et al. (2011) found that miR-9 may promote the proliferation of MKN45 and NUGC-3 gastric cancer cell lines by inhibiting CDX2 and its downstream targets (such as MUC2), which suggests that the anti-miR-9 drugs can indirectly regulate the expression of MUC2 and delay the progression of gastric cancer, which also has important significance for colorectal cancer. Here, CDX2 is linked to gastric cancer.